YU54602A - Drospirenon za terapiju zamene hormona - Google Patents

Drospirenon za terapiju zamene hormona

Info

Publication number
YU54602A
YU54602A YU54602A YUP54602A YU54602A YU 54602 A YU54602 A YU 54602A YU 54602 A YU54602 A YU 54602A YU P54602 A YUP54602 A YU P54602A YU 54602 A YU54602 A YU 54602A
Authority
YU
Yugoslavia
Prior art keywords
estrogen
menopausal
drospirenone
hormone replacement
replacement therapy
Prior art date
Application number
YU54602A
Other languages
English (en)
Inventor
Wolfgang Heil
Juergen Hilmann
Ralph Lipp
Rolf Schuermann
Original Assignee
Schering Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26071749&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU54602(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag. filed Critical Schering Ag.
Publication of YU54602A publication Critical patent/YU54602A/sh
Publication of RS52149B publication Critical patent/RS52149B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Farmaceutska kompozicija koja obuhvata kao prvi aktivni sastojak estrogen, kao sto je estradiol ili estradiol valerat, u dovoljnim kolicinama za tretiranja poremecaja i simptoma asociranih sa deficijentnim endogenim nivoima estrogena kod zena, i kao drugi aktivni sastojak 6ß, 7ß; 15ß;16ß-dimetilen-3-okso-17α-preg-4-ene-21,17,-karbolakton (drospirenon, DRSP) u dovoljnim kolicinama da zastiti endometrijum od negativnih efekata estrogena korisna, pored drugog, za tretiranje perimenopauzalnih, menopauzalnih i post-menopauzalnih zena. Ova kompozicija moze da se upotrebi za terapiju zamene hormona i moze da se primenjuje kao multi-fazovan farmaceutski preparat. Ova kombinaciona terapija moze da obuhvata kontinualnu, sekvencionalnu ili isprekidanu primenu, ili njihove kombinacije, DRSP i estrogen, svaki opciono u mikronizovanom obliku.
YU54602A 2000-01-18 2001-01-18 Farmaceutska kombinacija mikronizovanog drospirenona i estrogena za terapiju zamene hormona RS52149B (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48402600A 2000-01-18 2000-01-18
EP00200183 2000-01-18
PCT/IB2001/000041 WO2001052857A1 (en) 2000-01-18 2001-01-18 Drospirenone for hormone replacement therapy

Publications (2)

Publication Number Publication Date
YU54602A true YU54602A (sh) 2006-01-16
RS52149B RS52149B (sr) 2012-08-31

Family

ID=26071749

Country Status (30)

Country Link
EP (2) EP1611892B1 (sh)
JP (2) JP5128743B2 (sh)
KR (2) KR100913910B1 (sh)
CN (2) CN1395488A (sh)
AT (2) ATE442147T1 (sh)
AU (3) AU2001225413B2 (sh)
BG (1) BG65849B1 (sh)
BR (1) BR0107683A (sh)
CA (1) CA2394165C (sh)
CY (1) CY1109567T1 (sh)
CZ (1) CZ20022411A3 (sh)
DE (2) DE60113809T2 (sh)
DK (2) DK1257280T3 (sh)
EE (1) EE05533B1 (sh)
ES (2) ES2332226T3 (sh)
HK (2) HK1047248B (sh)
HU (1) HUP0204291A3 (sh)
IL (3) IL150775A0 (sh)
ME (1) ME00292B (sh)
MX (1) MXPA02006613A (sh)
NO (1) NO335570B1 (sh)
NZ (1) NZ520630A (sh)
PL (1) PL201878B1 (sh)
PT (1) PT1611892E (sh)
RS (1) RS52149B (sh)
RU (2) RU2275198C2 (sh)
SI (2) SI1611892T1 (sh)
SK (2) SK287719B6 (sh)
WO (1) WO2001052857A1 (sh)
ZA (2) ZA200206551B (sh)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1598069T3 (da) * 1999-08-31 2009-07-06 Bayer Schering Pharma Ag Farmaceutisk præparat af ethinylestradiol og drospirenon til anvendelse som præventionsmiddel
EP1216713A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
WO2003006027A1 (en) 2001-07-13 2003-01-23 Schering Aktiengesellschaft Combination of drospirenone and an estrogen sulphamate for hrt
DK1482948T3 (da) * 2002-03-11 2006-11-27 Janssen Pharmaceutica Nv Kontinuerlig sulfataseinhiberende progestogen-hormonsubstitutionsbehandling
MXPA04010682A (es) * 2002-04-26 2004-12-13 Schering Ag Tratamiento contra la hipertension en mujeres quienes reciben tratamiento restitutivo hormonal.
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
PT1558265E (pt) * 2002-11-05 2010-03-22 Bayer Schering Pharma Ag Utilização da drospirenona para o tratamento da hipertensão
AU2002368326A1 (en) * 2002-11-05 2004-06-07 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
PT1748756E (pt) * 2004-03-10 2009-07-20 Bayer Schering Pharma Ag Composições compreendendo drospirenona molecularmente dispersa
DE102004023984A1 (de) * 2004-05-14 2005-12-08 Hf Arzneimittelforschung Gmbh Filmförmiges, oral zu verabreichendes Arzneimittel, enthaltend Estriol
US8022053B2 (en) 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
CA2614187A1 (en) * 2005-07-15 2007-01-25 Bayer Schering Pharma Aktiengesellschaft Drospirenone containing transdermal drug delivery devices and methods of delivery thereof
DE102005056527A1 (de) * 2005-11-25 2007-07-12 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
DE102007011105A1 (de) * 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
CN101623287B (zh) * 2008-07-07 2012-02-08 天津金耀集团有限公司 一种屈螺酮类似物的治疗更年期综合症的药物组合物
ES2344675B1 (es) * 2008-12-19 2011-04-28 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
CA2795801C (en) * 2010-04-15 2018-05-29 Bayer Intellectual Property Gmbh Very low-dosed solid oral dosage forms for hrt
CA2796139A1 (en) 2010-04-15 2011-10-20 Bayer Intellectual Property Gmbh Low-dosed solid oral dosage forms for hrt
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
IN2014CN03307A (sh) 2011-11-04 2015-07-03 Bayer Pharma AG
TW201350122A (zh) * 2012-04-23 2013-12-16 Bayer Pharma AG １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
EA035687B1 (ru) 2015-06-18 2020-07-27 Эстетра Спрл Диспергируемая в полости рта единица дозирования, содержащая эстетрольный компонент
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
CN110809473A (zh) 2017-06-01 2020-02-18 延世大学校产学协力团 用于预防或治疗骨相关疾病的药物组合物
JOP20200260A1 (ar) * 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3022337A1 (de) * 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
JPH07114946B2 (ja) * 1988-10-24 1995-12-13 株式会社奈良機械製作所 難溶性物質の処理方法
JP2859919B2 (ja) * 1990-03-15 1999-02-24 旭化成工業株式会社 難溶性薬物の溶出性改善方法
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
JPH07112928A (ja) * 1993-10-15 1995-05-02 Freunt Ind Co Ltd 難溶性薬物の溶解性改善方法およびそれにより得られた粒状薬剤
JP4022269B2 (ja) * 1995-05-26 2007-12-12 協和醗酵工業株式会社 医薬組成物
US5922349A (en) * 1995-09-28 1999-07-13 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
JP2000515890A (ja) * 1996-07-26 2000-11-28 アメリカン・ホーム・プロダクツ・コーポレイション プロゲスチンとエストロゲンとの混合剤からなる一相性避妊法およびキット
DE19633685C1 (de) * 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
DE19654609A1 (de) * 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
JPH10182701A (ja) * 1996-12-26 1998-07-07 Sanei Toka Kk 溶出性向上粉末及びその製造方法
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
DK1598069T3 (da) * 1999-08-31 2009-07-06 Bayer Schering Pharma Ag Farmaceutisk præparat af ethinylestradiol og drospirenon til anvendelse som præventionsmiddel

Also Published As

Publication number Publication date
AU2541301A (en) 2001-07-31
RU2002122113A (ru) 2004-03-10
EP1611892A3 (en) 2006-02-01
BG65849B1 (bg) 2010-03-31
SK287719B6 (en) 2011-07-06
NZ520630A (en) 2004-09-24
PL201878B1 (pl) 2009-05-29
HUP0204291A2 (hu) 2003-04-28
WO2001052857A1 (en) 2001-07-26
NO20022966L (no) 2002-09-18
NO335570B1 (no) 2014-12-29
ME00292B (me) 2011-05-10
IL150775A (en) 2008-08-07
JP2009120615A (ja) 2009-06-04
EP1611892B1 (en) 2009-09-09
ES2247054T3 (es) 2006-03-01
EP1611892A2 (en) 2006-01-04
ES2332226T3 (es) 2010-01-29
HK1082433A1 (en) 2006-06-09
CZ20022411A3 (cs) 2003-02-12
EP1257280B1 (en) 2005-10-05
EE05533B1 (et) 2012-04-16
MXPA02006613A (es) 2003-10-15
NO20022966D0 (no) 2002-06-20
DE60113809T2 (de) 2006-06-22
PT1611892E (pt) 2009-11-20
SK288129B6 (sk) 2013-10-02
CN1395488A (zh) 2003-02-05
EP1257280A1 (en) 2002-11-20
BR0107683A (pt) 2002-11-12
KR20020088066A (ko) 2002-11-25
BG106915A (bg) 2003-04-30
SK10322002A3 (sk) 2003-03-04
RU2402331C2 (ru) 2010-10-27
HUP0204291A3 (en) 2003-05-28
ZA200206551B (en) 2006-04-29
RU2275198C2 (ru) 2006-04-27
HK1047248B (zh) 2005-12-30
DE60113809D1 (de) 2006-02-16
CA2394165C (en) 2010-04-13
RU2005140938A (ru) 2007-07-10
AU2001225413B2 (en) 2005-06-23
IL191131A (en) 2010-12-30
CA2394165A1 (en) 2001-07-26
JP2003520239A (ja) 2003-07-02
SI1257280T1 (sl) 2006-02-28
HK1047248A1 (en) 2003-02-14
CN101934078A (zh) 2011-01-05
AU2005209600B2 (en) 2008-08-07
PL356987A1 (en) 2004-07-12
DE60139907D1 (de) 2009-10-22
DK1611892T3 (da) 2009-11-02
ZA200601285B (en) 2008-01-08
CY1109567T1 (el) 2014-08-13
RS52149B (sr) 2012-08-31
KR100913910B1 (ko) 2009-08-26
IL150775A0 (en) 2003-02-12
MEP38008A (en) 2011-02-10
IL191131A0 (en) 2008-11-03
JP5128743B2 (ja) 2013-01-23
EE200200401A (et) 2003-10-15
KR20070051956A (ko) 2007-05-18
KR100747965B1 (ko) 2007-08-08
SI1611892T1 (sl) 2010-01-29
JP5563227B2 (ja) 2014-07-30
ATE442147T1 (de) 2009-09-15
ATE305789T1 (de) 2005-10-15
AU2005209600A1 (en) 2005-09-29
DK1257280T3 (da) 2005-12-12

Similar Documents

Publication Publication Date Title
YU54602A (sh) Drospirenon za terapiju zamene hormona
MADANES et al. Danazol
Sitruk-Ware et al. Pharmacological properties of mifepristone: toxicology and safety in animal and human studies
NZ516502A (en) Administration of non-oral androgenic steroids to women having an elevated level of sex hormone binding globulin (SHBG)
CA2205897A1 (en) Compositions and methods for contraception and for treatment of benign gynecological disorders
KR20090080989A (ko) 여성 리비도의 유지 및/또는 증가를 위한 경구 치료요법을 위한 디에노게스트와 조합된 에스트라디올 발레레이트 또는 17β-에스트라디올의 용도
RO121086B1 (ro) Utilizarea compuşilor cu proprietăţi antiestrogene, pentru controlul fertilităţii la femei
US20110009373A1 (en) Composition comprising a combination of an aromatase inhibitor, a progestin and an oestrogen and its use for the treatment of endometriosis
Samsioe Transdermal hormone therapy: gels and patches
CA2467237A1 (en) Method of preventing or treating benign gynaecological disorders
US20050222100A1 (en) Treatment of post-menopausal complaints in breast cancer patients comprising tibolone and a serm
JO2334B1 (en) Drospirenone for hormone replacement therapy
Shulman A review of drospirenone for safety and tolerability and effects on endometrial safety and lipid parameters contrasted with medroxyprogesterone acetate, levonorgestrel, and micronized progesterone
EP1007052B1 (en) Combinations of endometrial sparing progestins and endometrial atrophizing progestins with estrogens, in oral contraception
KR19990087672A (ko) 호르몬 대체 치료를 위한 순차적 에스트로겐/프로게스테론길항제 배합
Whitehead Hormone replacement therapy with estradiol and drospirenone: an overview of the clinical data
HRP20020666A8 (en) Drospirenone for hormone replacement therapy
Rozenberg Clinical evidence supporting the rationale for constant oestrogen, intermittent progestogen hormone replacement therapy
US20050124592A1 (en) Tibolone in the treatment of complaints associated with the administration of drugs which prevent the synthesis of endogenous estrogen
TH134365B (th) โดรสไพริโนนสำหรับการรักษาด้วยการแทนที่ฮอร์โมน
Schindler COMPOUND CEMICAL STRUCTURE Cimetidine Flutamide
MXPA98007513A (en) Sequencial combination of estrogen / antagonist of progesterone for therapy of replacement of hormo
AU5942700A (en) Sequential estrogen/progestrone antagonist combination for hormone replacement theapy
TH134365A (th) โดรสไพริโนนสำหรับการรักษาด้วยการแทนที่ฮอร์โมน